Latest Redmile Group, LLC Stock Portfolio
Redmile Group, LLC Performance:
2025 Q3: 20.89%YTD: 5.9%2024: -8.91%
Performance for 2025 Q3 is 20.89%, and YTD is 5.9%, and 2024 is -8.91%.
About Redmile Group, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Redmile Group, LLC reported an equity portfolio of $1 Billions as of 30 Sep, 2025.
The top stock holdings of Redmile Group, LLC are SRRK, KRYS, STOK. The fund has invested 14.2% of it's portfolio in SCHOLAR ROCK HLDG CORP and 11.4% of portfolio in KRYSTAL BIOTECH INC.
The fund managers got completely rid off KYMERA THERAPEUTICS INC (KYMR), HINGE HEALTH INC and BOSTON SCIENTIFIC CORP (BSX) stocks. They significantly reduced their stock positions in PRIME MEDICINE INC, REPLIMUNE GROUP INC (REPL) and AMICUS THERAPEUTICS INC (FOLD). The fund showed a lot of confidence in some stocks as they added substantially to IDEAYA BIOSCIENCES INC (IDYA), COGENT BIOSCIENCES INC (COGT) and IMMUNOME INC (IMNM).
The top stock holdings of Redmile Group, LLC are SRRK, KRYS, STOK. The fund has invested 14.2% of it's portfolio in SCHOLAR ROCK HLDG CORP and 11.4% of portfolio in KRYSTAL BIOTECH INC.
The fund managers got completely rid off KYMERA THERAPEUTICS INC (KYMR), HINGE HEALTH INC and BOSTON SCIENTIFIC CORP (BSX) stocks. They significantly reduced their stock positions in PRIME MEDICINE INC, REPLIMUNE GROUP INC (REPL) and AMICUS THERAPEUTICS INC (FOLD). The fund showed a lot of confidence in some stocks as they added substantially to IDEAYA BIOSCIENCES INC (IDYA), COGENT BIOSCIENCES INC (COGT) and IMMUNOME INC (IMNM).
Redmile Group, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Redmile Group, LLC made a return of 20.89% in the last quarter. In trailing 12 months, it's portfolio return was 1.83%.
New Buys
Additions
| Ticker | % Inc. |
|---|---|
| ideaya biosciences inc | 71.57 |
| cogent biosciences inc | 52.56 |
| immunome inc | 3.1 |
| neurogene inc | 1.75 |
Additions to existing portfolio by Redmile Group, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| prime medicine inc | -95.8 |
| replimune group inc | -88.51 |
| boundless bio inc | -58.33 |
| amicus therapeutics inc | -34.64 |
| rapt therapeutics inc | -12.38 |
| zymeworks inc | -10.72 |
| establishment labs hldgs inc | -5.22 |
| celldex therapeutics inc new | -4.67 |
Redmile Group, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| igm biosciences inc | -3,306,390 |
| kymera therapeutics inc | -35,055,500 |
| verve therapeutics inc | -8,313,130 |
| biohaven ltd | -10,293,500 |
| hinge health inc | -15,525,000 |
| 4d molecular therapeutics in | -416,143 |
| boston scientific corp | -9,162,180 |
| penumbra inc | -4,829,260 |
Redmile Group, LLC got rid off the above stocks
Sector Distribution
Redmile Group, LLC has about 89.4% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 89.4 |
| Others | 10.4 |
Market Cap. Distribution
Redmile Group, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 56.1 |
| MID-CAP | 22.7 |
| UNALLOCATED | 16.5 |
| MICRO-CAP | 4.1 |
Stocks belong to which Index?
About 78.1% of the stocks held by Redmile Group, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 78.1 |
| Others | 21.9 |
Redmile Group, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Redmile Group, LLC
Redmile Group, LLC has 40 stocks in it's portfolio. About 68.9% of the portfolio is in top 10 stocks. REPL proved to be the most loss making stock for the portfolio. STOK was the most profitable stock for Redmile Group, LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABSI | absci corporation | 2.44 | 8,253,320 | 25,090,100 | unchanged | 0.00 | ||
| ADCT | adc therapeutics sa | 6.10 | 15,666,700 | 62,666,900 | unchanged | 0.00 | ||
| ADGI | invivyd inc | 0.24 | 2,285,320 | 2,513,850 | unchanged | 0.00 | ||
| AKRO | akero therapeutics inc | 3.46 | 747,818 | 35,506,400 | reduced | -3.42 | ||
| ALXO | alx oncology hldgs inc | 0.59 | 3,332,980 | 6,099,360 | reduced | -1.72 | ||
| ANNX | annexon inc | 1.87 | 6,300,640 | 19,217,000 | unchanged | 0.00 | ||
| ATRA | atara biotherapeutics inc | 0.62 | 441,701 | 6,329,580 | unchanged | 0.00 | ||
| BEAM | beam therapeutics inc | 3.28 | 1,387,560 | 33,676,100 | reduced | -2.52 | ||
| BSX | boston scientific corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CLDX | celldex therapeutics inc new | 0.82 | 327,008 | 8,459,700 | reduced | -4.67 | ||
| COGT | cogent biosciences inc | 3.09 | 2,209,120 | 31,722,900 | added | 52.56 | ||
| ESTA | establishment labs hldgs inc | 0.52 | 129,364 | 5,302,630 | reduced | -5.22 | ||
| ETNB | 89bio inc | 2.11 | 1,473,140 | 21,655,100 | reduced | -4.66 | ||
| FATE | fate therapeutics inc | 1.58 | 12,872,900 | 16,219,900 | unchanged | 0.00 | ||
| FDMT | 4d molecular therapeutics in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FOLD | amicus therapeutics inc | 0.60 | 777,178 | 6,124,160 | reduced | -34.64 | ||
| IDYA | ideaya biosciences inc | 1.96 | 742,017 | 20,190,300 | added | 71.57 | ||
| IGMS | igm biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| IMNM | immunome inc | 5.72 | 5,023,380 | 58,823,800 | added | 3.1 | ||
| KROS | keros therapeutics inc | 0.85 | 552,506 | 8,740,640 | unchanged | 0.00 | ||